The Egyptian Drug Authority (EDA), represented by the Central Administration for Pharmaceutical Products, hereby announces the launch of a public consultation on the draft Notice to Applicants titled: "EG Human Pharmaceutical Module 1 Submission Guidance".

We are honored to receive your comments and suggestions via the designated "Stakeholder Feedback Form" sent to the following email address: hdr.regua.acc@edaegypt.gov.eg

This consultation period is open from October 15, 2026, until October 29, 2026.

This initiative reflects the EDA's commitment to developing and unifying the mechanisms and procedures for submitting human pharmaceutical product registration files, as well as enhancing the efficiency of regulatory requirements in line with international practices and standards.

To review the draft Notice to Applicants, please click on the following link